Numerate enters risk-sharing partnerships
that provide a cost-effective alternative to in-licensing or internal drug development.

Three of the key advantages of our partnership model:

We share risk with our partners. In all of our partnerships, we assume and mitigate the chemical design risk that exists from hit discovery to the nomination of the candidate.

You pay only as we are successful. We design, make, and when possible, test compounds. Our rewards are tied to our success, which means our partners pay us if our compounds satisfy the design criteria of our customers.

We offer flexible deal structures. Our partners range from academics working on emerging targets to large pharma companies looking for next-generation drugs. Accordingly, we are very flexible in how we structure our partnerships. We accommodate our partner’s preferred mix of short- and long-term success-based milestones.